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Abstract
Genotype imputation has the potential to assess human genetic variation at a lower cost than assaying the variants using
laboratory techniques. The performance of imputation for rare variants has not been comprehensively studied. We utilized
8865 human samples with high depth resequencing data for the exons and flanking regions of 202 genes and Genome-
Wide Association Study (GWAS) data to characterize the performance of genotype imputation for rare variants. We
evaluated reference sets ranging from 100 to 3713 subjects for imputing into samples typed for the Affymetrix (500K and
6.0) and Illumina 550K GWAS panels. The proportion of variants that could be well imputed (true r2.0.7) with a reference
panel of 3713 individuals was: 31% (Illumina 550K) or 25% (Affymetrix 500K) with MAF (Minor Allele Frequency) less than or
equal 0.001, 48% or 35% with 0.001,MAF,= 0.005, 54% or 38% with 0.005,MAF,= 0.01, 78% or 57% with
0.01,MAF,= 0.05, and 97% or 86% with MAF.0.05. The performance for common SNPs (MAF.0.05) within exons and
flanking regions is comparable to imputation of more uniformly distributed SNPs. The performance for rare SNPs
(0.01,MAF,= 0.05) was much more dependent on the GWAS panel and the number of reference samples. These results
suggest routine use of genotype imputation for extending the assessment of common variants identified in humans via
targeted exon resequencing into additional samples with GWAS data, but imputation of very rare variants (MAF,= 0.005)
will require reference panels with thousands of subjects.
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Introduction
Imputation and analysis of untyped genetic variants provides a
more comprehensive picture of genetic variation within a genomic
region than analysis of only typed variants [1]. It has been a key
tool contributing to the recent success of Genome-Wide
Association Studies (GWAS). Genotype imputation methods
combine haplotypes found in a study sample with the full
haplotypes available in a more densely genotyped reference set
to fill in missing genotypes. Imputation methods have been
extensively evaluated for imputing the genotypes of HapMap
SNPs into subjects with GWAS data [2]. The establishment of a
resource for imputation is one of the key aims of the 1000
Genomes Project [3]. In addition, studies sequencing specific
genes or the exome in thousands of subjects are available now [4],
at higher depth which enables the calling of individual genotypes
with error rates comparable with other genotyping methods. The
variants identified from high depth sequencing of the exons and
flanking regions of genes have a SNP density distribution quite
different than that available for the HapMap and 1000 Genomes
data where there are relatively few large gaps between variants,
and variants have an average inter-SNP distance of 875 bp [5]
and 200 bp [3], respectively. The variants identified in the coding
regions of genes are concentrated in short regions within a gene
interspersed with longer regions with no variants. Variants
genotyped by next generation sequencing methods yield very rare
heterozygous calls with higher confidence enabling novel variant
identification. High depth sequence data for thousands of samples
has resulted in high quality rare variant calls in minor allele
frequency (MAF) ranges not seen with prior HapMap or 1000
Genomes efforts. These efforts not only focused on sequencing a
smaller number of individuals but also used technologies with
lower confidence in very rare heterozygous calls. As sequencing
studies focusing on sequencing the exomes of genes are in progress,
characterizing the performance of imputation methods for variants
in the exons and flanking regions, especially for variants with MAF
less than or equal to 0.05, will provide a comprehensive picture of
the use of imputation to extend these association studies into
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24945
additional samples with GWAS data. Until now, no other study
has provided a summary of the performance of genotype
imputation for variants with minor allele frequencies less than
0.01.
There are a number of methods providing genotype imputation
including IMPUTE [6], MaCH [7], and BEAGLE [8]. All three
methods have been extended to accommodate multiple GWAS
platforms and reference panels with more than 1000 samples. We
selected BEAGLE for our analyses. A comparison of imputation
performance for minimac, http://genome.sph.umich.edu/wiki/
minimac, (an extention of MaCH software which takes haplotypes
as input) and BEAGLE, using data from chromosome 1, showed
them to be similar. For this chromosome, there were 111 and 152
SNPs with estimated r2 greater than 0.7 using minimac and
BEAGLE, respectively. The median true r2 for these sets of
variants was 0.977 and 0.982 for minimac and BEAGLE,
respectively (Figure S1). The corresponding mean genotype error
rates were 0.011 and 0.0124 and the mean allelic error rates were
0.0055 and 0.0062, for minimac and BEAGLE, respectively.
We recently completed high depth sequencing (median depth of
276) of the exons and flanking regions of 202 genes that are
current or prospective drug targets in over 14000 samples, 12514
of European ancestry (confirmed by principal component analysis ),
including population-based and case collections (described in the
Information S1) for 12 diseases. Analyses of experimental duplicates
and capillary sequencing for a subset of these samples yielded an
overall heterozygote genotype error rate of 0.50%. Of these
sequenced samples, 8865 have GWAS data, including the
Affymetrix 500K (n = 3983), Affymetrix 6.0 (n = 573) and Illumina
550K (n = 4309) GWAS platforms. We used subsets of these
samples in an evaluation where we partitioned sequenced samples
into reference and ‘‘to-be-imputed’’ study sets and compared the
imputed genotypes with genotypes derived from high depth
sequence data from the DeepSeq Variant Set.
Our primary goal was to develop a strategy for genotype-
phenotype analysis utilizing genotype imputation for this dataset.
We characterized the performance of genotype imputation with
reference panels ranging from 100 to 3713 subjects for variants
distributed within the exons and flanking regions of genes. Our
results show that genotype imputation into additional samples with
GWAS data will increase the sample size available for genotype-
phenotype analysis for common and moderately rare variants with
performance depending on the reference panel size for very rare
variants (MAF,0.005).
Results
This evaluation focused on characterizing the performance of
genotype imputation for reference panels of 100 to 3713 subjects
and variants present in the exons and flanking regions of genes. As
the DeepSeq Variant Set had high quality genotype calls derived
from high depth sequence data for 8865 subjects, we were able to
characterize genotype imputation performance for variants with
minor allele frequencies less than 0.01. We first summarize how
well the estimated r2, the ratio of the variance of the imputed
allelic dosage and the variance of the true allelic dosage assuming
Hardy- Weinberg equilibrium [7], correlates with true r2, squared
correlation of the true allelic dosage and the imputed allelic dosage
[7] based on non-integer dosages which incorporate uncertainty in
the imputed genotypes, for all reference and study samples listed in
Table 1.
Figure 1 plots the estimated r2 versus true r2 for the Affymetrix
500K dataset with 3713 reference samples for variants with MAF
no greater or greater than 0.005 which removes almost all variants
with poorly calibrated estimated r2 values. This plot is shown for
Affymetrix 500K data set with 3713 reference samples, but the
results for all other datasets are similar. The Pearson correlation
coefficients relating true and estimated r2 for variants with
MAF#0.005 were 0.787, 0.825, 0.783 for Affymetrix 500K data
set with n = 3713, Affymetrix 6.0 data set with n = 562, and
Illumina 550K data set with n = 3713 reference samples,
respectively. The Pearson correlation coefficients relating true
and estimated r2 for these same reference sets for variants with
0.005,MAF#0.5 were 0.951, 0.971, and 0.983. These results
illustrate that the estimated r2 calculated for imputed markers
reflects the true r2 obtained when genotype data is available
making the reported estimated r2 a valuable metric of imputation
quality for markers with MAF greater than 0.005. Estimated r2 is
likely to under estimate true r2 for extremely rare variants
(MAF#0.005). We also note that this correlation was stronger in
our smaller, more ethnically homogeneous reference sets (n#1200)
as opposed to our largest reference sets (n = 3713).
For common SNPs, the impact of a reference sample with
variants from the exons and flanking regions of genes rather than
more uniformly spaced as would be available in HapMap 3 [2],
can be illustrated by comparing our median true r2 to those
obtained from imputing SNPs for each Illumina 550k SNP
present in the HapMap but not available on the Affymetrix 500K
panel. Figure 2 plots median true r2 for variants with
0.01#MAF#0.5 for 300, 600, and 1200 reference samples in
Europeans [[ along with median true r2 for 300, 600, and 1200
reference samples for the Affymetrix 500K platform calculated
using variants from the DeepSeq Variant Set that were matched
based on MAF to their variants. The median true r2 values for
these datasets are very similar except for variants with
MAF#0.05 illustrating that imputation using reference samples
with variants from the exons and flanking regions of genes is
similar to more uniformly spaced markers. For variants with
MAF#0.05, the median true r2 for the variants identified by
Table 1. Data sets used for characterizing genotype imputation.
Platform
Total number of samples with
sequence data Reference set sizes evaluated Study set size used
Affymetrix 500K 3983 100, 300, 600, 1200, 3713 270
Affymetrix 6.0 573 100, 300 270
Affymetrix 6.0 573 562 11
Illumina 550K 4309 100, 300, 600, 1200, 3713 270
We partitioned the total number of samples with sequence data into reference samples and ‘‘to-be-imputed’’ study samples. We used the reference panel samples to
predict unobserved genotypes in the study sample.
doi:10.1371/journal.pone.0024945.t001
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sequencing is much lower than that for variants that are on the
Illumina 550K panel which were chosen because they are good
proxies for other SNPs [2].
Figure 3 plots the median true r2 calculated for MAF bins versus
MAF in the reference sample for all variants present in the
DeepSeq Variant Set. For variants with 0.05,MAF#0.5, the
number of reference samples and the GWAS platform have a
minimal effect on the median true r2, even when the reference
panel size is 100 (data not shown). For variants with
0.01,MAF#0.05, the number of reference samples begins to
have more of an effect but in this frequency range the GWAS
platform is more influential. In this frequency bin, the median true
r2 values are 0.80, 0.80 and 0.62 for reference sample sets of 600
(562 for Affymetrix 6.0) versus 0.73, 0.72 and 0.48 for reference
sample sets of 300 for the Illumina 550K, Affymetrix 6.0 and
Affymetrix 500K panels, respectively. For variants with
MAF#0.01, both number of reference samples and the GWAS
platform influence the median true r.2 The median true r2 for
variants with 0.005,MAF#0.01 for 300 reference samples ranges
from 0.07 to 0.23 depending on the GWAS platform but for 600
reference samples, it ranges from 0.19 to 0.48. This illustrates the
importance of larger reference samples for imputing variants with
MAF#0.01. For variants with 0.005,MAF#0.01, the median
true r2 values for a reference sample size of 600 are 0.48 for the
Illumina 550K and Affymetrix 6.0 panels versus 0.19 for the
Affymetrix 500K panel. For reference panels with greater than
approximately 600 samples when imputing variants with
0.005,MAF#0.01, utilizing the Affymetrix 500K panel results
in median true r2 values about 0.2 lower than those for the
Illumina 550K panel.
Figure 4 shows the cumulative distribution function of the true r2
for different reference sample sizes for variants with
0.001,MAF#0.005, 0.005,MAF#0.01, and 0.01,MAF#0.05.
For variants with 0.001,MAF#0.005, the proportion of well
imputed SNPs (true r2.0.7) was approximately 48% for the
Illumina 550K data set with n = 3713 reference samples and less
than 35% for the remaining reference sets. Comparing the three
panels in Figure 4 illustrates that reference sample size has more of
an influence than GWAS panel as the MAF of the variant decreases.
Furthermore, the proportion of well imputed variants remains
approximately 54% for the Illumina 550K data set with n = 3713
reference samples even for variants with 0.005,MAF#0.01. For
common SNPs with MAF.0.05, greater than 86% of these SNPs
can be well imputed (true r2.0.7) when using GWAS platforms that
rely on tagging SNPs or the largest reference panel for the
Affymetrix 500K data set with n = 3713 reference samples, data not
shown.
Discussion
We characterized the performance of genotype imputation with
reference panels of 100 to 3713 subjects for variants with spacing
that would be representative of extending our evaluation of
variants identified via exon-targeted sequencing into additional
samples for three GWAS panels. Even with reference sample sets
of 100 subjects, greater than 80% of variants with MAF.0.05 can
be well imputed (estimated r2.0.7). For variants with
0.01,MAF,0.05, the proportion of well imputed variants is
dependent on the number of reference samples and the GWAS
panel but it can be as high as 50–70% for reference panels larger
than 1200. An appreciable number of variants with MAF#0.005,
can be well imputed with reference panels including 3713 subjects
and more comprehensive GWAS panels (i.e. 48% of variants with
0.001#MAF#0.005 for the Illumina 550K platform will be well
imputed with a reference panel of 3713 individuals). We
investigated how missing data in the reference panel (from the
DeepSeq Variant Set) affected the estimated r2 which revealed
Figure 1. True r2 versus the estimated r2. True r2, squared
correlation of the true allele dosage (based on genotypes derived from
DeepSeq Variant Set), is plotted versus the estimated r2, the ratio of the
variance of the imputed allelic dosage and the variance of the true
allelic dosage assuming Hardy- Weinberg equilibrium for each imputed
variant, for the reference set consisting of 3713 samples with Affymetrix
500K GWAS data. Very rare variants, MAF#0.005, (1331 variants) and
more common variants, MAF.0.005, (1776 variants) are shown
separately. These results illustrate that while the estimated r2 calculated
for imputed markers reflects the true r2 obtained when genotype data
is available for common and rare variants, it is likely to under estimate
the true r2 for very rare variants.
doi:10.1371/journal.pone.0024945.g001
Figure 2. Median true r2 for array and exon-derived variants in
MAF bins. The median true r2 for 0.01#MAF#0.5 for 300, 600, and
1200 reference samples, derived from imputing Illumina 550K SNPs not
available on the Affymetrix 500K platform (shown in black), and median
true r2 for 300, 600, and 1200 reference samples for Affymetrix 500K
platform, calculated using DeepSeq Variant Set (shown in red), are
plotted versus minor allele frequency bins. Bins were defined to be
centered on MAFs ranging from [0.01, 0.49] with a total width of 0.02.
The median true r2 values for these datasets are very similar except for
variants with MAF#0.05 illustrating that imputation using reference
samples with variants from the exons and flanking regions of genes is
similar to more uniformly spaced markers.
doi:10.1371/journal.pone.0024945.g002
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that missing rates less than 30% have little impact on the
distribution of estimated r2 values (data not shown).
Our comparisons of imputing markers with uniform spacing
versus imputing markers derived from the DeepSeq Variant Set
showed no discernable differences for markers with MAF.0.05.
These results are informative with respect to what can be expected
for imputation with HapMap3 data where the SNP density is
higher and the number of samples of European ethnicity is now
205 [2]. For moderately rare SNPs (0.01,MAF#0.05), the
median true r2 values are lower, similar to results found in analysis
of HapMap 3 and ENCODE data that showed that array SNPs,
especially those selected on the basis of LD, are much more likely
to be good proxies for each other in comparison with newly
discovered variants. We did not compare these results to
genotyping imputation using the 1000 Genomes dataset as a
reference panel since the current 1000 Genomes dataset is derived
from low depth sequencing data.
This analysis provides one of the first evaluations of imputation
for variants identified in the exons and flanking regions of genes,
especially for variants with MAF less than or equal to 0.05.
Deriving variants from high depth sequence data enabled us to
evaluate imputation performance by comparing imputed SNPs to
variants at very low frequencies which are generally unreliably
genotyped using other assay methods. For moderately rare SNPs,
0.01,MAF#0.05, the GWAS platform was an important factor
for high quality imputation. The Illumina 550K GWAS platform
includes tag SNPs derived from greater than 2 million common
SNPs genotyped in HapMap Phase 2 data [9] which were selected
after sequencing a few individuals so that rare haplotypes are not
well-represented. The Affymetrix 500K platform includes SNPs
selected on the basis of sequence constraints when choosing the
probes and additional tag SNPs were added to form the Affymetrix
6.0 array. Therefore, it is not surprising that imputation
performance is better for GWAS platforms that focused on SNPs
Figure 3. Median true r2 versus MAF bins. The median true r2 for the MAF bins of (0,0.0005], (0.0005, 0.001], (0.001, 0.002], (0.002, 0.005], (0.005,
0.01], (0.01, 0.02], (0.02, 0.05], (0.05, 0.1], (0.1, 0.2], and (0.2, 0.5] are plotted versus MAF in the reference sample for the DeepSeq Variant Set. Reference
set samples sizes of 300, 600, 1200, and 3713 were available for both Affymetrix 500K (shown in red) and Illumina 550K (shown in black) platforms.
Reference set sizes of 300 and 562 were available for the Affymetrix 6.0 platform (shown in blue). Median true r2 values are near to 1.0 for variants
with MAF$0.1. For variants with MAF,0.1, the number of reference samples and the GWAS platform both influence the median true r2.
doi:10.1371/journal.pone.0024945.g003
Figure 4. Cumulative distribution function of true r2. The cumulative distribution function, the proportion of markers with a true r2 greater
than the threshold, is shown for all reference sample sizes and GWAS platforms described in Figure 3. The proportion of well imputed variants
decreases as the variant MAF decreases.
doi:10.1371/journal.pone.0024945.g004
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that are good proxies for nearby SNPs. Analysis of the relationship
between maximum pairwise R2LD for any SNP within 1 Mb and
true r2, observed for that SNP showed that for common markers,
SNPs that are well tagged by GWAS panels will almost always be
well imputed but being well tagged by a single marker from the
GWAS panel is not a requirement for high imputation quality.
This suggests that higher order linkage disequilibrium provides
information on untyped variants and contributes to the imputation
quality. For rare and very rare SNPs, 0,MAF#0.01, the number
of reference samples becomes more of a factor since observing
multiple copies of a SNP is important for establishing the
haplotype background for observed SNPs. Figure 3 provides the
median true r2 value which summarizes imputation quality but
fails to convey the distribution of true r2 values for each MAF bin.
For almost all reference set sizes and GWAS platforms, the
distribution of true r2 values is negatively skewed for MAFs greater
than 0.01 and positively skewed for MAFs less than 0.01.
Our study provides a description of imputation performance for
multiple GWAS panels using reference panels up to 3713 subjects
with variants derived from high depth sequence data from the
exons and flanking regions of genes. Very rare variants
(MAF,0.005) are unlikely to be imputable without reference
panels with greater than 1200 subjects, while almost all common
SNPs (MAF$0.05) and approximately 40% of rare variants
(0.005,MAF,0.05) for reference panel sizes of 1200 individuals
or more will be imputable. Therefore, genotype imputation into
additional samples with GWAS data will increase the sample size
available for genotype-phenotype analysis for common and
moderately rare variants with performance depending on the
reference panel size for very rare variants (MAF,0.005).
Materials and Methods
Ethics Statement
GSK collected human blood in collaborative research trials with
investigators during 2002–2010 for other studies. Written
informed consent was obtained and recorded via electronic case
report form. The consents allowed for continued or future
evaluation of variants associated with diseases. The work described
in this manuscript represents a re-use of these samples and data
and no new human interventions were conducted. Therefore this
research involves the study of existing samples and data. No
additional IRB approvals were sought for this specific portion of
the work. The names of all ethics committee/institutional review
boards that approved the original protocols for sample collection
include: Committee on Human Research, University of Califor-
nia, San Francisco, Ethics Committee of Basel City and Canton,
Basel University Hospital, Medical Ethics Committee University
Medical Centre, Amsterdam for the Multiple Sclerosis gene MSA
collection; Committee on Ethics in Clinical Research, CHUV,
Lausanne University, Lausanne, Switzerland for the CoLaus
collection; Regional Committee for Medical Research Ethics
(REKIII), Faculty of Medicine, University of Bergen, Norway for
the GenKOLs collection, Ethics Committee Multicentre Trials,
Bulgaria, McGill University Health Center Research Ethics
Board, Montreal, Canada, Office of Research Services Clinical
Research Ethics Board, University of British Columbia, Canada,
Capital Health Research Ethics Board, Halifax, Canada, Ham-
ilton Health Sciences/Faculty of Health Sciences Research Ethics
Board, Hamilton, Ontario, Canada, Providence Health Care
Research Institute, Vancouver, British Columbia, Canada,
Comite´ d’e´thique de la recherche, Que´bec, Canada, Queens
University Office of Research Services, Kingston, Ontario,
Canada, Multicentric Ethics Committee Fakultni nemocnice v
Motole, Prague, Czech Republic, Den videnskabsetiske komite´ for
region hovedstaden, METC Zuidwest-Holland, MHHA Kirkels-
Breukers, Delft, The Netherlands, Regional Ethic Committee
West, Haukeland University Hospital, Bergen, Norway, The
National Medical Ethics Committee of the Republic of Slovenia,
Ljubljana, Slovenia, Comite´ e`tic d’investigacio´ clı´nica Illes Balears,
Palma de Mallorca, Spain, Oxfordshire REC C, Bicester, United
Kingdom, MD Human Subjects Committee, Torrance, Califor-
nia, USA, Research/Human Subjects Committee, St Elizabeth’s
Medical Center, Boston, Massachusetts, US, Goodwyn Institution
Review Board, Cincinnati, Ohio, US, Western International
Review Board, Olympia, Washington, US, Baylor College of
Medicine IRB, Houston, Texas, US, Committee for the Protection
of Human Subjects, Dartmouth-Hitchcock Medical Center,
Hanover, New Hampshire, US, National Jewish Medical &
Research Center IRB, Denver, Colorado, US, University of
Nebraska Medical Center IRB, Omaha, Nebraska, US, Yale
University School of Medicine Human Investigation Committee,
New Haven, Connecticut, US, Mayo Foundation IRB, Rochester,
Minnesota, US, Creighton University Medical Center IRB,
Omaha, Nebraska, University of Pittsburgh IRB, Pittsburgh, PA,
US, Brigham & Women’s Hospital IRB, Boston, Massachusetts,
US, John Hopkins School of Medicine, Baltimore, MD, St Francis
Hospital & Medical Center IRB, Hartford, Connecticut, US for
the ECLIPSE Study; MedStar Research Institute Institutional
Review Board, Washington Health Center Research Committee
for the Coronary Artery Disease Medstar study; Bayerische
Landesa¨rztekammer (Bavarian Ethics Committee) for the Unipo-
lar Depression Study; University Research Ethics Committee of
the University of Dundee, The Joint South London and Maudsley
and The Institute of Psychiatry NHS Research Ethics Committee
London, UK, Center for Addiction and Mental Health Research
Ethics Board, Toronto, Canada for the Bipolar Disorder Study;
MREC for Scotland, Edinburgh, Scotland, Health Sciences
Research Ethics Committee, Laval University, Canada, Ethics
Committee of the Medical Faculty of Ludwig Maximilian
University, Munich, Germany for the Schizophrenia study,
University of Western Ontario Research Ethics Board for Health
Sciences Research Involving Human Subjects, Ontario, Canada,
Centre Hospitalier regional de Trois-Rivieres comite d’ethique de
la recherche´, Trois-Rivieres, Quebec, Canada, Centre for
Addiction and Mental Health Research Ethics Board, University
of Toronto, Toronto, Canada, University of Western Ontario
Research Ethics Board for Health Sciences Research Involving
Human Subjects, Ontario, Canada, SCO Health Service
Research Ethics Board, Ottawa, Ontario, Canada, University
Health Network Research Ethics Board, Toronto, Canada,
University of British Columbia Clinical Research Ethics Board,
Vancouver, British Columbia, Canada, Douglas Hospital Re-
search Ethics Board, Montreal, Quebec, Canada for the
Alzheimer’s Disease GenADA study; Committee on Human
Research, University of California-San Francisco, California, US,
Royal Adelaide Hospital Research Ethics Committee, University
of Texas Southwestern Medical Center at Dallas Institutional
Review Board, Dallas, Texas, US, Human Research Ethics Board
of the University of Ottawa Heart Institute, Ottawa, Ontario,
Canada, and University of Lausanne, Ethics Committee, Lau-
sanne, Switzerland for the Metabolic Syndrome GEMS study,
Regional Committee for Medical Research Ethics, Sør Health
Region, Oslo Norway for the Epilepsy HiTDIP study; and
Cantonal Ethics committee of the Canton of Zurich, Specialized
Sub-Committee for Psychiatry, Neurology, Neurosurgery, Zurich,
Switzerland for the Epilepsy GenEpa study.
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Analyses were carried out using 8865 subjects for whom we had
genotype data derived from high-depth sequencing data and
commonly used GWAS panels to characterize genotype imputa-
tion for variants found in the exons and flanking regions [10–20].
The high-depth of sequence, including 850 kb sequence data
used in this experiment, were generated by BGI (Shenzhen, China)
by sequencing the exons plus 50 bp of flanking sequence of 202
genes resulting in approximately 8351 kb of coding and 323 kb of
noncoding (untranslated) exons. Candidate variants were identified
for each sample where a genotype was called with a minimum
sequencing depth of four, a minimum consensus quality of 20 with
no other variants within four base pairs. Genotypes were called in all
samples for all variant positions identified by aggregating all
sequenced samples. Consensus genotypes were called at these
position bases for each sample with a minimum depth of seven and
minimum consensus quality of 20. The median sequence depth per
sample was 276. Samples were excluded from the data if 1) their
average sequencing depth was less than 10, 2) sequence-based
genotypes were more than 15% discordant with genome-wide panel
genotypes or 3) the sample was sequenced multiple times and had
lower average sequencing depth. Analysis of 133 sample duplicates
resulted in a discordance rate among heterozygous genotype calls of
0.90% with lower rates in more common variants. An overall
heterozygote genotype error rate was estimated to be 0.50%. These
quality settings resulted in median genotype missingness of 0.0069,
0.011, 0.014, and 0.021 for variants with MAF#0.001,
0.001,MAF#0.005, 0.005,MAF#0.05, MAF.0.05, respectively.
In contrast to other genotyping platforms, subject-level genotype
missing rates were not correlated with genotype accuracy. We
removed variants with a missing rate greater than 30% and singleton
variants since they cannot be phased for imputation. This ‘‘DeepSeq
Variant Set’’ included 9077 variants.
Our sample consisted of 8865 samples with sequence data as
described above and GWAS data for one of the following
platforms: Affymetrix 500K, (n = 3983), Illumina 550K (n = 4309)
and Affymetrix 6.0 (n = 573). Due to the large number of
sequenced samples in our experiment, we partitioned these
sequenced samples into reference sets and ‘‘to-be-imputed’’ study
sets. We used the densely genotyped reference panel to predict
unobserved genotypes in the study sample using genotype
imputation. Then we compared the imputed genotypes to
genotypes in the DeepSeq Variant Set. Table 1 lists the reference
set and study set sizes evaluated. We selected reference set sizes of
100, 300, 600, 1200 and 3713 to enable comparisons with [8;21]
for uniformly spaced variants and between the Affymetrix 500K
and Illumina 550K platforms. The reference set size of 562 (see
Table 1) for the Affymetrix 6.0 platform was the result of
partitioning the sequenced samples into reference (98% of the
overall sample) and study samples (2% of the overall sample)
multiple times holding out study samples, sequentially, so that we
developed a set of imputed genotypes for each sample. For each
variant in the DeepSeq Variant Set, we also calculated pairwise R2
(due to linkage disequilbrium – R2LD) with all SNPs within 1 Mbp
on each GWAS panel.
Genotype imputation analysis was carried out using BEAGLE
with the default settings. All GWAS SNPs within 1 Mbp of the
sequenced regions were included in the analysis. When genotypes
were missing in the reference panel, they were imputed based on
the available data similarly to missing data in the study sample. We
calculated the true r2 or the squared correlation of the true allele
dosage (based on genotypes derived from DeepSeq Variant Set)
and the imputed allele dosage for each dataset [8]. This measure
quantifies the similarity of the imputed allele dosage with the
dosage based on genotypes. We also calculated the estimated r2
(MACH’s ratio of variances metric), the ratio of the variance of the
imputed allelic dosage and the variance of the true allelic dosage
assuming Hardy- Weinberg equilibrium for each imputed variant
[7]. This is a metric of expected imputation quality.
To compare the imputation quality of BEAGLE and minimac,
we imputed chromosome 1 data using the Affymetrix 500K
reference set of 3713 subjects with 270 study subjects using both
programs. Minimac imputation was run using 10 rounds and 300
states as parameters. Running times were 310 minutes for
BEAGLE and 160 minutes for minimac, respectively. We
compared true r2, estimated r2, mean genotypic error rate (among
the variants), and mean allelic error rate (among variants). The
allelic or genotypic error rate is the proportion of allelic or
genotypic mismatches among all allelic or genotypic comparisons.
Supporting Information
Figure S1 Cumulative distribution functions of the true
r2 for minimac and BEAGLE. The cumulative distribution
function, the proportion of markers with an estimated r2 greater
than the threshold, is shown for reference sample size of 3713 for
chromosome 1 markers for the Affymetrix 500K platform.
Imputation performance is similar for the two analysis methods.
(TIF)
Information S1
(DOC)
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